Mark Siegel - NuVim Sec Counsel
| NUVM Stock | USD 0 0.00 0.00% |
Insider
Mark Siegel is Sec Counsel of NuVim Inc
| Phone | 302-827-4052 |
| Web | https://www.nuvim.com |
NuVim Management Efficiency
The company has return on total asset (ROA) of (1.9239) % which means that it has lost $1.9239 on every $100 spent on assets. This is way below average. NuVim's management efficiency ratios could be used to measure how well NuVim manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MR | Aerovate Therapeutics | 62 | |
| George Eldridge | Aerovate Therapeutics | 61 | |
| Rudolf Bless | Bank of America | N/A | |
| Matthew Koder | Bank of America | 52 | |
| Jared Allenbach | Recursion Pharmaceuticals | N/A | |
| Bernard Mensah | Bank of America | 53 | |
| Alfonso Villanueva | PayPal Holdings | N/A | |
| Amie OToole | Alphabet Inc Class C | 49 | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| Aditya Bhasin | Bank of America | 50 | |
| Bruce Thompson | Bank of America | 56 | |
| Thomas Scrivener | Bank of America | 52 | |
| Fiona Cicconi | Alphabet Inc Class C | 58 | |
| Anne Finucane | Bank of America | N/A | |
| Shafique MD | Recursion Pharmaceuticals | 53 | |
| Lauren Mogensen | Bank of America | 58 | |
| Kent Walker | Alphabet Inc Class C | 63 | |
| Rita Cook | Bank of America | N/A | |
| Hunter MD | Aerovate Therapeutics | 58 | |
| Al Mcrae | Bank of America | N/A | |
| Timothy MBA | Aerovate Therapeutics | 62 | |
Management Performance
| Return On Asset | -1.92 |
NuVim Inc Leadership Team
Elected by the shareholders, the NuVim's board of directors comprises two types of representatives: NuVim inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NuVim. The board's role is to monitor NuVim's management team and ensure that shareholders' interests are well served. NuVim's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NuVim's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Kundrat, Chairman of the Board, CEO, CFO | ||
| Mark Siegel, Sec Counsel |
NuVim Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is NuVim a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.92 | |||
| Operating Margin | (5.35) % | |||
| Current Valuation | 245.43 K | |||
| Shares Owned By Institutions | 0.98 % | |||
| Price To Earning | (0.55) X | |||
| Price To Sales | 8.18 X | |||
| Revenue | 1.06 K | |||
| Gross Profit | 23.7 K | |||
| Net Income | (26.7 K) | |||
| Total Debt | 135.92 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in NuVim Pink Sheet
NuVim financial ratios help investors to determine whether NuVim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NuVim with respect to the benefits of owning NuVim security.